Become an Industry Collaborator

The Industry Collaboration Team (ICT) is an annual GOG Foundation membership program designed and developed to foster and facilitate a two-way communication channel between Industry and the GOG Foundation. We strive to build a strong partnership with Industry in order to serve as their research and collaboration partner, paving the way for advancement in the field of gynecologic oncology.

Member Benefits and Opportunities

  • Provides the opportunity to establish a two-way communication channel between industry and the GOG Foundation
  • For a more rapid accumulation of information for pooling knowledge by multidisciplinary organizations and industry
  • Fosters interaction between leaders in oncology and industry
  • An opportunity to extend information about new and improving technologies, equipment, products, and services to
    professionals working in gynecologic cancer research
Member BenefitsPreferred $25,000Standard $6,000

Foundation Support:

  • Support Clinical Trial Research
  • Promote awareness through research
  • New Investigator mentoring

Meeting Registration Badge Fee:

Representatives attending will receive complimentary badge fee along with relevant CME certificate(s)



Representatives attending will receive complimentary badge fee and CME certificate (Pre-registration only)

  • Additional representatives to register $125/each ($150/each On-site)
Additional Benefits
Your company profile on gog.orgYesYes
A direct link to your websiteYesYes
Recognition on meeting signsYesYes

Advisory Board Meeting Discount

Preferred members will receive a 20% discount to host an advisory Board meeting during NRG Oncology Semiannual meetings. GOG Foundation will act as your meeting planner and coordinate the event for up to 10 advisors for an additional fee (contact us for a detailed brochure). Please contact us to inquire about Advisory Board meetings held outside of the NRG Oncology Semiannual
meeting at (410) 721-7126 or via email at or

(Standard Level members can request an upgraded membership for an Ad Board)

ICT Reception Invitation

An Invitation Only opportunity to join GOG Foundation Board of Directors and Committee Members at the ICT Reception.

Yes Four (4) AttendeesYes Two (2) Attendees

One–on-One Sessions:

Meet with up to five (5) GOG Partners Members to discuss a topic of your choice for one 40 minute session




Company Website

To address healthcare challenges across the world, we unite a biotech spirit with the strength of a successful pharmaceutical business. The result is a biopharmaceutical company combining science, passion, and expertise to improve health and healthcare in new ways. Making a remarkable impact in people’s lives is more than our promise. It’s our purpose.


Company Website

Agenus is an immuno-oncology company driven by innovation. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.


Company Website


Company Website

Bayer is a world-class innovation company with a 150-year history. Our scientific successes are intended to help improve people’s lives. At the same time, our innovations form the basis for sustainable and profitable business activity and are the key to maintaining or achieving leadership positions in all of our markets.

Our products are helping to address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources.

  • We are improving people’s quality of life by preventing, alleviating or curing diseases.
  • We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based
    raw materials.
  • Our high-tech polymer materials are making significant contributions in areas such as energy and resource efficiency for mobility, construction and home living.

In line with our mission “Bayer: Science For A Better Life,” we aim to improve people’s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.

Bristol-Myers Squibb

Company Website

Bristol-Myers Squibb is the world leader in providing life-saving and life-extending therapies for people with cancer. All of the company’s considerable resources and expertise in oncology are marshaled toward the single goal of providing safer and more effective anticancer medicines. The mission of Bristol-Myers Squibb Oncology is to extend and enhance the lives of people living with cancer.

Clovis Oncology

Company Website

Clovis is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Eli Lilly and Company

Company Website

Eli Lilly and Company is a leading innovation-driven corporation and is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

Lilly Oncology is committed to providing comprehensive healthcare solutions – answers that matter – for oncologists and cancer patients around the world through the discovery and development of breakthrough cancer medicines.

Genentech Bioncology

Company Website

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Genentech manufactures and commercializes several major oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.


Company Website

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.


Company Website

We are a biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer.


Company Website

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapies.

ImmunoGen, Inc.

Company Website

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen’s highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla®. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at


Company Website

Mersana Therapeutics

Company Website


Company Website

Palti’s initial research from his basement laboratory has evolved to become an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.

We launched Optune® – our Tumor Treating Fields delivery system for glioblastoma (GBM) – in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, we received U.S. Food and Drug Administration (FDA) approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide. We actively market for that indication in the United States, Germany and Switzerland.

The science of Tumor Treating Fields has the potential to extend beyond GBM. We have five ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. We presented our phase 2 pilot data in pancreatic and ovarian cancers at our research and development day on Dec. 12, 2016. In 2016, we began our phase 3 pivotal trial in brain metastases originating from NSCLC. In 2017, we started our phase 3 pivotal trial in NSCLC. Internationally, more than 20 institutions are studying the effects of Tumor Treating Fields in cancer treatment.

Our company began with a patient-forward approach that continues to drive our mission today. With more than 15 years of research and many significant milestones, we have established ourselves as an innovator in oncology dedicated to improving the lives of cancer patients.

Pfizer Oncology

Company Website

Pfizer is a research-based global pharmaceutical company dedicated to helping people live longer, healthier lives. It invests more than $2 billion annually in research, searching for treatments and cures for cancer, osteoporosis, diabetes, Alzheimer’s disease, arthritis, heart disease, sexual dysfunction, and a wide variety of other diseases. Pfizer is also a leader in animal health, offering medicines for companion and farm animals, and in consumer health care products.

Seattle Genetics

Company Website

VBL Therapeutics

Company Website

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is currently being studied in a Phase 3 pivotal trial for Recurrent Glioblastoma (rGBM). The trial is being conducted under an FDA Special Protocol Assessment (SPA), and VB-111 has obtained fast track and Orphan designations.